Conference appearance puts Doximity (DOCS) in focus for telehealth investors

Doximity (DOCS) heads into its ViVE 2026 conference appearance in Los Angeles, with CEO Jeffrey Tangney presenting, keeping attention on how its digital tools and telemedicine platform might support the business.

Despite the upcoming ViVE appearance and interest in its telehealth tools, Doximity’s share price return has been weak over longer periods. It has a 30 day share price return of 29.10% and a 1 year total shareholder return of 61.96%, while the 7 day share price return of 8.36% hints at some short term momentum picking up again.

If this conference spotlight has you looking across digital health, it could be a good moment to scan a wider set of healthcare names using our 31 healthcare AI stocks as a starting list of ideas.

With Doximity reportedly trading at a 43% intrinsic discount and more than 50% below analyst targets, yet following a 62% decline in 1-year total shareholder return, is this weakness a potential opportunity or is the market already fully reflecting its future prospects in the current price?

Most Popular Narrative: 58.4% Undervalued

At a last close of $26.44 against a widely followed fair value of about $63.57, the current price sits well below the narrative’s estimate. This puts the focus squarely on the assumptions behind that gap.

The expanded adoption of AI powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time supporting long term revenue and margin expansion.

Curious what kind of revenue growth, margin profile, and future earnings multiple are baked into that fair value? The narrative leans on specific multi year forecasts and a premium valuation hurdle that many investors might not expect.

Result: Fair Value of $63.57 (UNDERVALUED)

However, you also need to weigh the risk that extensive free AI features and ongoing reliance on pharmaceutical marketing budgets could stall the bullish thesis if monetization lags.

Next Steps

With the article leaning toward an undervalued angle, it makes sense to look at the underlying facts yourself and move quickly if you want to shape your own view, especially by weighing the 4 key rewards alongside the risks already discussed.

Looking for more investment ideas?

If Doximity has sharpened your focus on quality, do not stop here. Use the screener to line up more names that actually fit your approach.

• Target quality at a discount by scanning 47 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying strength.
• Prioritise staying power by reviewing solid balance sheet and fundamentals stocks screener (41 results) where stronger financial footing can help support business resilience across different conditions.
• Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.